Post-earnings recap
Reported
Mon, May 9, 2022
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
75%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Krystal Biotech's earnings report showed a significant loss per share, which contributed to a sharp decline in stock price. The lack of revenue figures and guidance left investors uncertain about the company's financial trajectory. The stock's 12.28% drop reflects investor concerns about the company's performance and future outlook.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.99 | N/A | -107.29% |
| Revenue | N/A | N/A | N/A |
Management acknowledged the challenges faced during the quarter. They emphasized their commitment to advancing their pipeline despite the lack of financial guidance.
Management did not provide specific revenue figures or guidance for the upcoming quarters.
The company is focusing on its ongoing clinical trials and product development.